Presentación    
TRANSLATIONAL ONCOLOGY
Composition
Name
Position
Institution
Jaime Feliú Batlle
Jefe de Servicio de Oncología Médica
Profesor Titular de Oncología
Hospital Universitario La Paz
Universidad Autónoma de Madrid
Jorge Barriuso Feijoó
Facultativo Especialista de Área en Oncología
Hospital Universitario La Paz
Borja Belandía Gómez
Científico Titular
IIB "Alberto Sols"
Beatriz Castelo Fernández
Facultativo Especialista de Área en Oncología
Hospital Universitario La Paz
Paloma Cejas Guerrero
Investigadora Postdoctoral
Hospital Universitario La Paz
Roberto Crespo San Pedro
Técnico Superior en Anatomía Patológica
Hospital Universitario La Paz
Ana Belén Custodio Carretero
Facultativo Especialista de Área en Oncología
Hospital Universitario La Paz
Esther Díaz López
Técnico de Laboratorio
Hospital Universitario La Paz
Enrique Espinosa Arranz
Facultativo Especialista de Área en Oncología
Profesor Asociado
Hospital Universitario La Paz
Universidad Autónoma de Madrid
Juan Ángel Fresno Vara
Investigador Senior (Contrato Miguel Servet - I2)
Jefe de Laboratorio
Hospital Universitario La Paz
Ángelo Gámez Pozo
Investigador Postdoctoral (Contrato Técnico de Apoyo)
Hospital Universitario La Paz
Ismael Ghanem Cañete
Médico Adjunto en Oncología Médica
Hospital Universitario La Paz
Victoria María Heredia Soto
Investigadora Postdoctoral
Hospital Universitario La Paz
Juan Carlos Lacal Sanjuán
Profesor de Investigación
IIB "Alberto Sols"
Rocío López Vacas
Técnico de Laboratorio (Contrato Técnico de Apoyo)
Hospital Universitario La Paz
Virginia Martínez Marín
Facultativo Especialista de Área en Oncología
Hospital Universitario La Paz
Víctor Moreno García
Facultativo Especialista de Área en Oncología
Hospital Universitario La Paz
Juan Moreno Rubio
Investigador Postdoctoral
Hospital Universitario La Paz
Ignacio Palmero Rodríguez
Científico Titular
IIB "Alberto Sols"
Álvaro Pinto Marín
Facultativo Especialista de Área en Oncología
Hospital Universitario La Paz
Andrés Redondo Sánchez
Facultativo Especialista de Área en Oncología
Profesor Asociado
Hospital Universitario La Paz
Universidad Autónoma de Madrid
Nuria Rodríguez Salas
Facultativo Especialista de Área en Oncología
Hospital Universitario La Paz
Pilar Zamora Auñón
Facultativo Especialista de Área en Oncología Profesor Asociado
Hospital Universitario La Paz
Universidad Autónoma de Madrid
Strategic Objective
The aim of cancer research is to improve understanding of all aspects of the disease, including deepening our understanding of the biology of the tumour, developing new treatments, analysing the efficacy of diagnostic tests and performing studies aimed at prevention and early diagnosis.
Although important advances have been made in recent years in our understanding of the origin and evolution of cancer, their implementation in healthcare takes too much time. The Translational Oncology Unit (TOU) was established with the objective of facilitating the incorporation into clinical practice of new advances in molecular biology and the technology developed in this field.
The Translational Oncology group’s objective is to conduct highly scientific applied research in such a way that basic research can be rapidly translated to clinical practice. In other words, cancer patients at La Paz University Hospital benefit almost immediately from the results of research conducted by their own physicians.
The main lines of study are based on tumours with the greatest incidence and impact on survival, such as lung, colorectal, breast and ovarian cancer, although other types of neoplasms have been incorporated such as gastric and renal cancer. A series of fundamental objectives have been established for these neoplasms that can be summarised as early diagnosis, molecular classification for therapeutic goals and the search for individualised treatments. The majority of TOU projects have as their primary objective the search for predictors of susceptibility or resistance to anticancer agents and the search for prognostic factors related to the evolution of the tumour.
Research Lines
• Identification of prognostic factors Clinical Genomic Proteomic.
• Identification of mechanisms of resistance to drugs.
• Efficacy and toxicity of antineoplastic therapies.
• Palliative care and supportive treatments.